N/A N=168 Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percentage of Responders — 80; 87.2; 76.7 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=205 Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…
N/A N=115 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face
Age-related Volume Deficit in the Mid-face
Primary: Subject Experience Measured by Patient Satisfaction Questionnaire — 1.94; 1.62; 1.51 Units on a scale
N/A N=103 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency
Mid-face Volume Deficiency
Primary: Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 4 — 97.06 percentage of…
N/A N=60 Pan Facial Volume Restoration
Volume Loss (Soft Tissue Ptosis or Atrophy )
Primary: Mean Change From Baseline in Volume Loss Assessment — -0.8 Score on a scale
N/A N=16 Jowl Improvement With Injectable Fillers
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
N/A N=29 JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose
Asian Nose Enhancement
Primary: Percentage of Participants With a ≥ 1 Grade Improvement on the Assessment of Aesthetic Improvement Scale (AAIS) as Assessed by the Central Evaluating Physician at Day…
N/A N=270 GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
Cheek Augmentation
Primary: Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS) — -1.4; -0.1; -1.3 score on a scale
Phase 3 N=168 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population
Temple Hollowing
Primary: Number of Participants With Adverse Events — 23; 59; 1; 2 Participants
N/A N=169 Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants
N/A N=282 Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
Mid-facial Volume Deficit Related to Aging
Primary: Responder Rate Based on Improvement in Score on Validated 6-point Mid-Face Volume Deficit Scale (MFVDS) — 85.6; 38.9 percentage of responders
N/A N=11 A Prospective Evaluation of Infraorbital Filler Injection
Dermal Filler · Rejuvenation
Primary: Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 — -0.026; -0.065; -0.108 cc
N/A N=60 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula
Age-related Volume Deficit in the Mid-face
Primary: Change From Baseline in Mid-Face Volume Deficit Scale (MFVDS) Score — 3.5; 3.5; -1.8; -1.9 score on a scale
Phase 4 N=101 Prospective Evaluation of Facial Cosmetic Procedures
Cosmetic Techniques
Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
Phase 3 N=140 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
Infraorbital Hollowing
Primary: Percentage of Participants With at Least a 1-point Improvement Change From Baseline on the Allergan Infraorbital Hollows Scale (AIHS) Based on Evaluating Investigator's…
N/A N=192 A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation
Chin Retrusion
Primary: Percentage of Participants With a ≥ 1-point Improvement (Decrease) on the Allergan Chin Retrusion Scale (ACSR) Score — 56.3; 27.5 percentage of participants — p=0.0019
Phase 4 N=25 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces
Aging
Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05
Phase 3 N=171 A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old
Temple Hollowing
Primary: Percentage of Participants With ≥ 1-grade Improvement From Baseline in the Validated Allergan Temple Hollowing Scale (ATHS) Based on Evaluating Investigator (EI)…
Phase 1 N=20 Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
HIV Facial Lipoatrophy
Primary: Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Prinicple Investigator — 19 participants
N/A N=80 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area
Infra-orbital Skin Depressions
Primary: Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the Allergan Infra-Orbital Rating Scale (AIRS) on the Right and Left Side — 99…
N/A N=148 Restylane Defyne for Correction of Chin Retrusion
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
N/A N=110 Saypha® Volume LIdocaine in Nasolabial Folds
Moderate to Severe Nasolabial Folds
Primary: Responder Rate in Reduction of Nasolabial Folds — 34; 39; 73 Participants
N/A N=164 Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults
Nose Enhancement
Primary: Volume Change From Baseline in the Nose Area — -0.005; 2.032 cubic centimeters (cc) — p=<0.0001
Phase 3 N=206 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
Phase 4 N=18 Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study
Infraorbital Hollows
Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…
N/A N=201 RHA®4 for Midface Volume Deficiency
Cheek Augmentation · Correction of Age-related Midface Contour Deficiencies
Primary: Non-inferiority of RHA®4 to the Change From Baseline for Subjects Treated With Comparator Product at 8 Weeks After the Last Treatment as Assessed by the BLE Using the…
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
N/A N=180 Morphological Pattern of the Atrophic Posterior Maxillae
Bone Deficiency, Posterior Maxillae
Primary: Lateral Wall Thickness — 161 mm
Phase 4 N=53 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions
Cheek Line Depressions
Primary: Percentage of Participants by Improvement Rating (Improved and Not Improved) of Their Dynamic Radial Cheek Lines as Assessed by the Participant Using the Global…